CSLSeqirusistheonlymanufacturertoofferadifferentiatedinfluenzavaccineforalleligiblepeopleagedsixmonthsandolderintheUnitedStates.
CSL-Seqirus是唯一一家为美国所有6个月及以上符合条件的人群提供分化型流感疫苗的制造商。
CentersforDiseaseControlandPrevention(CDC)trendfindingsindicateasignificantdeclineininfluenzavaccinationrates,whichposesaseriousrisktopublichealthinfrastructureandunderscorestheimportanceofreceivinganannualinfluenzavaccination.1,2
AccordingtotheCDC,itisrecommendedthatalleligiblepeopleagedsixmonthsandolderreceivetheirannualinfluenzavaccine,especiallypeopleatanincreasedriskofsevereinfluenza-relatedcomplications,suchasolderadults,pregnantpeople,andchildrenunderfiveyearsold.2,3
SUMMIT,N.J.,July9,2024/PRNewswire/--CSLSeqirus,abusinessofCSL(ASX:CSL),todayannouncedthatithascommencedshippingitsdifferentiatedportfolioofinfluenzavaccines.Thisyear,thecompany'sinfluenzavaccinesarebeingproducedastrivalentinfluenzavaccine(TIV)formulations,incompliancewiththeU.S.
新泽西州SUMMIT，2024年7月9日/PRNewswire/-CSL-Sevirus，CSL（ASX:CSL）的一家企业，今天宣布，它已经开始推出其差异化的流感疫苗组合。今年，该公司的流感疫苗正在生产三价流感疫苗（TIV）配方，符合美国。
FoodandDrugAdministration's(FDA)directivetoremovetheB/Yamagatastrain.4.
美国食品和药物管理局（FDA）指令删除B/Yamagata菌株。
'Weareproudtosupporthealthcareprovidersintheireffortstovaccinatetheirpatientsandcommunitiestohelpturnaroundconcerningdeclinesinseasonalinfluenzavaccinationrates,'saidStefanMerlo,VicePresidentofCommercialOperations,NorthAmerica,CSLSeqirus.'Weareacommittedpartnerinpublichealthandaredoingourparttoeducate,inform,andmeettheevolvingneedsofthepublic,ensurecustomersarepreparedfortheupcomingfluseason,andhelpreversethisdownwardtrendtorestorevaccinationrates.'.
CSLSequirus北美商业运营副总裁斯特凡·梅洛（StefanMerlo）说：“我们很自豪地支持医疗保健提供者为患者和社区接种疫苗，以帮助扭转季节性流感疫苗接种率下降的局面。”我们是公共卫生领域的坚定合作伙伴，正在尽自己的力量教育、告知和满足公众不断变化的需求，确保客户为即将到来的流感季节做好准备，并帮助扭转这种下降趋势，恢复疫苗接种率。”。
Thisseason,the2024/25influenzavaccineportfolioforCSLSeqirus,theonlymanufacturertoofferadifferentiatedinfluenzavaccineoptionapprovedforuseinpeopleagedsixmonthsandolder,includes:
本季，针对CSL-Seqirus的2024/25流感疫苗组合是唯一一家提供经批准用于6个月及以上人群的差异化流感疫苗选择的制造商，包括：
FLUCELVAX(InfluenzaVaccine),thefirstandonlycell-basedinfluenzavaccineindicatedforuseinpeoplesixmonthsandolder.5
FLUCELVAX（流感疫苗），这是第一种也是唯一一种适用于6个月及以上人群的基于细胞的流感疫苗。5
FLUAD(InfluenzaVaccine,Adjuvanted),thefirstandonlyadjuvantedseasonalinfluenzavaccineforadults65andolder,whichispreferentiallyrecommendedbytheCentersforDiseaseControlandPrevention's(CDC)AdvisoryCommitteeonImmunizationPractices(ACIP)overstandard-doseinfluenzavaccines.6,7.
FLUAD（流感疫苗，佐剂），是第一种也是唯一一种针对65岁及以上成年人的佐剂季节性流感疫苗，由疾病控制和预防中心（CDC）免疫实践咨询委员会（ACIP）优先推荐，而不是标准剂量的流感疫苗[6,7]。
FLUADcontainsanMF59adjuvantthatisdesignedtostrengthen,broaden,andlengthentheimmuneresponsewhenaddedtoaninfluenzavaccine.6,8,9
FLUAD含有MF59佐剂，当添加到流感疫苗中时，该佐剂旨在增强，扩大和延长免疫反应。6,8,9
AFLURIA(InfluenzaVaccine),anegg-based,influenzavaccineapprovedforuseineligiblepeoplesixmonthsofageandolder.10
AFLURIA（流感疫苗），一种基于鸡蛋的流感疫苗，被批准用于六个月及以上的合格人群
Theimpactofdecliningvaccinationratesposesaseriousrisktopublichealthinfrastructure,withpreliminaryestimatesfromtheCDCreportinganincreaseininfluenza-relatedhospitalizationsanddeathslastseason,incomparisontoseasonsprior,aswellasanoverburdenedhealthcaresystem.11,12Acrossallagecohorts,vaccinationratesexperienceddouble-digitpercentagedeclinesoverthepastthreefluseasonsaccordingtointernalcalculationsbasedoninfluenzatrackingdata.13Thisincludesanotable22%dropamongchildrenaged6monthsto18yearsanda14%decreaseinadultsover65,agroupthattypicallymaintainsstableimmunizationrates.13.
Additionally,thepublichealthburdenofinfluenzaoutpacesotherrespiratoryillness.11,14,15Duringthe2023/24fluseason,influenzaaccountedfornearlyhalfofhospitalizationsattributedtoinfectiousdiseasesincludinginfluenza,COVIDandrespiratorysyncytialvirus(RSV)combinedandoverhalfoftotaldeaths.11,14,15ThisdataunderscorestheimportanceoftheCDC'srecommendationthatalleligiblepeopleagedsixmonthsandolderreceiveanannualinfluenzavaccinationasanessentialmeasuretohelppreventinfluenzaanditscomplications.2Thisisespeciallyimportantforthoseatanincreasedriskofsevereinfluenza-relatedcomplications,suchasolderadults,pregnantpeople,andchildrenunderfiveyearsold.3.
'Influenzacontinuestoposeasignificantthreat,asevidencedbyrecentfluseasons,'saidDr.GreggSylvester,ChiefHealthOfficer,CSLSeqirus.'AswebegindistributinginfluenzavaccinestohealthcareprovidersthroughouttheU.S.,itisimperativethatweworktomaintainhighvaccinationratesthisseasontohelpreducetheburdenofinfluenza-relatedillnessesandtheriskofsevereoutcomes.'.
ForadditionalinformationonourinfluenzavaccinesfortheupcomingfluseasonaswellasresourcesaboutvaccinationcampaignsandCDCguidance,visitflu360.com.
有关即将到来的流感季节流感疫苗的更多信息，以及有关疫苗接种活动和CDC指导的资源，请访问flu360.com。
AboutCSLSeqirusCSLSeqirusispartofCSL(ASX:CSL).Asagloballeaderintheprotectionofpublichealthandoneofthelargestinfluenzavaccineprovidersintheworld,CSLSeqirusiscommittedtopreventinginfectiousdiseases,likeinfluenzaandCOVID-19,andisatranscontinentalpartnerinpandemicpreparedness.
关于CSL-sequirusCSL-sequirus是CSL的一部分（ASX:CSL）。作为保护公共卫生的全球领导者和世界上最大的流感疫苗供应商之一，CSL-Sevirus致力于预防流感和新型冠状病毒等传染病，并且是大流行防备的跨洲合作伙伴。
Withstate-of-the-artproductionfacilitiesintheU.S.,theU.K.andAustralia,andleadingR&Dcapabilities,CSLSeqirusoffersabroadportfolioofinnovative,differentiatedvaccinesinmorethan20countriesaroundtheworld..
凭借在美国、英国和澳大利亚拥有最先进的生产设施，以及领先的研发能力，CSL-Sevirus在全球20多个国家提供了广泛的创新、差异化疫苗组合。。
FormoreinformationaboutCSLSeqirus,visitwww.CSL.com.
有关CSL-Seqirus的更多信息，请访问www.CSL.com。
AboutCSLCSL(ASX:CSL;USOTC:CSLLY)isaglobalbiotechnologycompanywithadynamicportfoliooflifesavingmedicines,includingthosethattreathaemophiliaandimmunedeficiencies,vaccinestopreventinfluenza,andtherapiesinirondeficiencyandnephrology.Sinceourstartin1916,wehavebeendrivenbyourpromisetosavelivesusingthelatesttechnologies.
关于CSLCSL（ASX:CSL；USOTC:CSLLY）是一家全球生物技术公司，拥有动态的救生药物组合，包括治疗血友病和免疫缺陷的药物，预防流感的疫苗以及缺铁和肾脏病的疗法。自1916年成立以来，我们一直致力于使用最新技术拯救生命。
Today,CSL–includingourthreebusinesses:CSLBehring,CSLSeqirusandCSLVifor–provideslifesavingproductstopatientsinmorethan100countriesandemploys32,000people.Ouruniquecombinationofcommercialstrength,R&Dfocusandoperationalexcellenceenablesustoidentify,developanddeliverinnovationssoourpatientscanlivelifetothefullest.
如今，CSL（包括我们的三大业务：CSLBehring、CSLSequirus和CSLVifor）为100多个国家的患者提供救生产品，拥有32000名员工。我们独特的商业实力、研发重点和卓越运营相结合，使我们能够识别、开发和提供创新，使我们的患者能够过上最充实的生活。
Forinspiringstoriesaboutthepromiseofbiotechnology,visitCSLBehring.com/VitaandfollowusonTwitter.com/CSL..
FormoreinformationaboutCSL,visitwww.CSL.com.
有关CSL的更多信息，请访问www.CSL.com。
IntendedAudienceThispressreleaseisissuedfromCSLSeqirusinSummit,NewJersey,USAandisintendedtoprovideinformationaboutourglobalbusiness.PleasebeawarethatinformationrelatingtotheapprovalstatusandlabelsofapprovedCSLSeqirusproductsmayvaryfromcountrytocountry.PleaseconsultyourlocalregulatoryauthorityontheapprovalstatusofCSLSeqirusproducts..
Forward-LookingStatementsThispressreleasemaycontainforward-lookingstatements,includingstatementsregardingfutureresults,performanceorachievements.Thesestatementsinvolveknownandunknownrisks,uncertaintiesandotherfactorswhichmaycauseouractualresults,performanceorachievementstobemateriallydifferentfromanyfutureresults,performancesorachievementsexpressedorimpliedbytheforward-lookingstatements.
Thesestatementsreflectourcurrentviewswithrespecttofutureeventsandarebasedonassumptionsandsubjecttorisksanduncertainties.Giventheseuncertainties,youshouldnotplaceunduerelianceontheseforward-lookingstatements..
USA-CRP-24-0016
美国-CRP-24-0016
MEDIACONTACTTiffanyCody+1(908)370-1863Tiffany.Cody@Seqirus.com
媒体联系人TiffanyCody+1（908）370-1863Tiffany.Cody@Seqirus.com
FLUAD(InfluenzaVaccine,Adjuvanted),FLUCELVAX(InfluenzaVaccine),andAFLURIA(InfluenzaVaccine)
FLUAD（流感疫苗，佐剂），FLUCELVAX（流感疫苗）和AFLURIA（流感疫苗）
IMPORTANTSAFETYINFORMATION
重要安全信息
WhatareFLUAD(InfluenzaVaccine,Adjuvanted),FLUCELVAX(InfluenzaVaccine),andAFLURIA(InfluenzaVaccine)FLUADisavaccinethathelpsprotectpeopleaged65yearsandolderfromtheflu.
什么是FLUAD（流感疫苗，佐剂），FLUCELVAX（流感疫苗）和AFLURIA（流感疫苗）？FLUAD是一种有助于保护65岁及以上人群免受流感感染的疫苗。
FLUCELVAXandAFLURIAarevaccinesthathelpsprotectpeopleaged6monthsandolderfromtheflu.
FLUCELVAX和AFLURIA是帮助保护6个月及以上人群免受流感感染的疫苗。
Vaccinationwithanyofthesemaynotprotectallpeoplewhoreceivethevaccine.
接种任何这些疫苗都可能无法保护所有接种疫苗的人。
WhoshouldnotreceiveFLUAD,FLUCELVAX,orAFLURIAYoushouldnotreceiveFLUADnorAFLURIAifyouhaveahistoryofsevereallergicreactions(e.g.,anaphylaxis)toanycomponentofthevaccine,includingeggprotein,ortoapreviousinfluenzavaccine.
谁不应该接受FLUAD，FLUCELVAX或AFLURIA？如果您对疫苗的任何成分（包括蛋蛋白）或以前的流感疫苗有严重的过敏反应（例如过敏反应）史，则不应接受FLUAD或AFLURIA。
YoushouldnotreceiveFLUCELVAXifyouhaveahistoryofsevereallergicreactions(e.g.,anaphylaxis)toanycomponentofthevaccine.
如果您对疫苗的任何成分有严重过敏反应（例如过敏反应）史，则不应服用FLUCELVAX。
BeforereceivingFLUAD,FLUCELVAX,orAFLURIA,tellyourhealthcareprovideraboutallmedicalconditions,includingifyou:
在接受FLUAD、FLUCELVAX或AFLURIA之前，请告知您的医疗保健提供者所有医疗状况，包括您是否：
haveeverhadGuillain-Barrésyndrome(severemuscleweakness)withinsixweeksaftergettingafluvaccine.Thedecisiontogiveanyfluvaccineshouldbemadebyyourhealthcareprovider,basedoncarefulconsiderationofthepotentialbenefitsandrisks
接种流感疫苗后六周内曾患过格林-巴利综合征（严重肌肉无力）。您的医疗保健提供者应在仔细考虑潜在益处和风险的基础上，决定是否接种流感疫苗
haveproblemswithyourimmunesystemoraretakingcertainmedicationsthatsuppressyourimmunesystem,asthesemayreduceyourimmuneresponsetothevaccine
你的免疫系统有问题，或者正在服用某些抑制免疫系统的药物，因为这些药物可能会降低你对疫苗的免疫反应
haveeverfaintedwhenreceivingavaccine
曾在接种疫苗时晕倒
WhatarethemostcommonsideeffectsofFLUAD,FLUCELVAX,andAFLURIA
FLUAD、FLUCELVAX和AFLURIA最常见的副作用是什么？
pain,tenderness,redness,itching,bruising,and/orswellingwherethevaccinewasgiven
注射疫苗的地方有疼痛、压痛、发红、瘙痒、瘀伤和/或肿胀
headache
头痛
extremetiredness
极度疲劳
muscleaches
肌肉酸痛
feelingunwell(malaise)
感觉不适（不适）
Additionalsideeffectsseeninchildreninclude:
儿童的其他副作用包括：
raisedhardenedareawherethevaccinewasgiven
接种疫苗的凸起硬化区域
changesineatinghabits/lossofappetite
饮食习惯改变/食欲不振
sleepiness
嗜睡
irritability
易怒
diarrhea
腹泻
ThesearenotallthepossiblesideeffectsofFLUAD,FLUCELVAX,andAFLURIA.Youcanaskyourhealthcareproviderformoreinformationandforadviceaboutanysideeffectsthatconcernyou.
。
WhatdoIdoifIhavesideeffectsReportanysevereorunusualsideeffectstoyourhealthcareprovider.
如果我有副作用该怎么办？向您的医疗保健提供者报告任何严重或异常的副作用。
ToreportSUSPECTEDADVERSEREACTIONS,contactCSLSeqirusat1-855-358-8966orVAERSat1-800-822-7967orwww.vaers.hhs.gov.
Beforereceivinganyofthesevaccines,pleaseseethefullUSPrescribingInformationforFLUAD,FLUCELVAX,orAFLURIA.YoucanaskyourhealthcareproviderorpharmacistforinformationaboutFLUAD,FLUCELVAX,orAFLURIAthatiswrittenforhealthcareprofessionals.
在接受任何这些疫苗之前，请参阅美国有关FLUAD，FLUCELVAX或AFLURIA的完整处方信息。您可以向您的医疗保健提供者或药剂师咨询为医疗保健专业人员编写的有关FLUAD，FLUCELVAX或AFLURIA的信息。
REFERENCES
参考文献
AccessedJune2024.5FLUCLEVAX.PackageInsert.CSLSeqirusInc.6FLUAD.PackageInsert.CSLSeqirusInc.7GrohskopfLA,BlantonLH,FerdinandsJM,etal.PreventionandControlofSeasonalInfluenzawithVaccines:RecommendationsoftheAdvisoryCommitteeonImmunizationPractices—UnitedStates,2023–24InfluenzaSeason.
2024.5年6月访问FLUCLEVAX。包装插页。CSLSeqirusInc.6FLUAD。。CSLSeqirusInc.7GrohskopfLA，BlantonLH，FerdinandsJM等。用疫苗预防和控制季节性流感：免疫实践咨询委员会的建议-美国，2023-24流感季节。